| [1] |
Saleh K, Fernandez A, Pasquier F. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults[J]. Cancers (Basel), 2022, 14(7):1805.
doi: 10.3390/cancers14071805
|
| [2] |
Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia[J]. Blood, 2015, 125(24):3711-3719.
doi: 10.1182/blood-2015-02-627935
|
| [3] |
Jiang Q, Huang XJ, Chen Z, et al. Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): results of pivotal (phase Ⅱ) trials[J]. Blood, 2020, 136(Suppl 1):50-51.
|
| [4] |
Jiang Q, Li ZR, Hou Y, et al. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP) with T315I mutation[J]. Blood, 2022, 140(Suppl 1):203-204.
|
| [5] |
Jabbour E, Kantarjian HM, Koller PB, et al. Update of olverembatinib (HQP1351) overcoming ponatinib and/or asciminib resistance in patients (Pts) with heavily pretreated/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)[J]. Blood, 2023, 142(Suppl 1):1798
|
| [6] |
Liang E, Min P, Xiong Y, et al. Olverembatinib (HQP1351) enhances antitumor effects of chemotherapy in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)[J]. Blood, 2023, 142(Suppl 1):5882
|
| [7] |
Liu W, Wang C, Ouyang W, et al. Efficacy and safety of olverembatinib in adult BCR: : ABL1-positive ALL with T315I mutation or relapsed/refractory disease[J]. Br J Haematol, 2024, 205(6):2228-2233.
|
| [8] |
Zhu Y, Huang J, Wang Y, et al. Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia[J]. Ann Hematol, 2024, 103(11):4643-4648.
doi: 10.1007/s00277-024-06027-w
|
| [9] |
Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial[J]. J Hematol Oncol, 2022, 15(1):113.
doi: 10.1186/s13045-022-01334-z
|
| [10] |
中国临床肿瘤学会(CSCO)白血病专家委员会. 奥加伊妥珠单抗治疗急性淋巴细胞白血病临床应用指导原则(2023年版)[J]. 白血病·淋巴瘤, 2023, 32(8):449-456.
doi: 10.3760/cma.j.cn115356-20230518-00116
|
|
Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO). Guideline principles for clinical application of inotuzumab ozogamicin in treatment of acute lymphoblastic leukemia (2023 version)[J]. J Leuk Lymphoma, 2023, 32(8):449-456.
doi: 10.3760/cma.j.cn115356-20230518-00116
|
| [11] |
Short NJ, Jabbour E, Jain N, et al. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions[J]. J Hematol Oncol, 2024, 17(1):32.
doi: 10.1186/s13045-024-01552-7
|
| [12] |
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia[J]. N Engl J Med, 2016, 375(8):740-753.
doi: 10.1056/NEJMoa1509277
|
| [13] |
Kantarjian HM, Stock W, Cassaday RD, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the INO-VATE trial: CD22 pharmacodynamics, efficacy, and safety by baseline CD22[J]. Clin Cancer Res, 2021, 27(10):2742-2754.
doi: 10.1158/1078-0432.CCR-20-2399
|
| [14] |
Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review[J]. Bone Marrow Transplant, 2018, 53(4):449-456.
doi: 10.1038/s41409-017-0019-y
|
), XI Rui, PAN Yaozhu, WANG Zonghui, TIAN Hongjuan, MAO Dongfeng, WU Tao*(
